We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Try the New Site
We're building a modernized ClinicalTrials.gov! Visit Beta.ClinicalTrials.gov to try the new functionality.
ClinicalTrials.gov Menu

Involvement of Endogenous Digitalis-like Compounds in Breast Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00310882
Recruitment Status : Withdrawn (the PI is no longer work at Hadassah)
First Posted : April 5, 2006
Last Update Posted : April 8, 2011
Information provided by:
Hadassah Medical Organization

Brief Summary:

The endogenous digitalis-like compounds (DLC)are steroid hormones synthesized and released from the adrenal gland.They are integrated in the feed-back system of the Hypothalami-Pituitary-Adrenal gland axis.One of their remarkable function is to induce apoptosis in malignant cells. Recently, accumulating data point to the possibility of using synthetic DLC as new anti-cancer drugs. Less is known about the endogenous metabolism of these compounds in cancer patients.

Proceeding from preliminary clinical data which demonstrated significantly reduced DLC plasma levels in breast cancer patients and from in vitro data which showed an impaired release of DLC towards stress stimuli in athymic nude mice,we put up the hypothesis that a latent adrenal insufficiency with low DLC levels facilitates the induction and progression of tumor diseases.

Condition or disease
Breast Neoplasms Fibrocystic Disease of Breast Mammaplasty

Show Show detailed description

Layout table for study information
Study Type : Observational
Estimated Enrollment : 250 participants
Observational Model: Case-Control
Time Perspective: Prospective
Official Title: Involvement of Endogenous Digitalis-like Compounds in Breast Cancer
Study Start Date : May 2006
Estimated Study Completion Date : May 2008

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Breast Cancer
Drug Information available for: Digitalis

Biospecimen Retention:   Samples Without DNA
blood samples

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes
Sampling Method:   Probability Sample
Study Population
Women with first diagnosis of Breast Cancer or a benign Breast Disease

Inclusion Criteria:

  • first visit to a Breast Disease Ambulance for consultation
  • no pregnancy

Exclusion Criteria:

  • no severe heart disease (EF > 40%)
  • no therapy with digitalis
  • no acute/chronic inflammatory disease (e.g. RA, M. Crohn)
  • no dysfunction of the Hypothalamo-Pituitary-Adrenal system
  • no severe mental disorder

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00310882

Layout table for location information
Hadassah Hebrew University Medical Centers
Jerusalem, Israel
Sponsors and Collaborators
Hadassah Medical Organization
Layout table for investigator information
Principal Investigator: Heidrun Weideman Hadassah Hebrew University Medical Centers
Layout table for additonal information
Responsible Party: Dr. Tanir Allweiss, Hadassah Medical Organization
ClinicalTrials.gov Identifier: NCT00310882    
Other Study ID Numbers: 297-31.3-06-HMO-CTIL
First Posted: April 5, 2006    Key Record Dates
Last Update Posted: April 8, 2011
Last Verified: May 2008
Keywords provided by Hadassah Medical Organization:
breast cancer
digitalis like compounds
prognostic factor
Additional relevant MeSH terms:
Layout table for MeSH terms
Breast Neoplasms
Cystic Fibrosis
Fibrocystic Breast Disease
Breast Diseases
Neoplasms by Site
Skin Diseases
Pancreatic Diseases
Digestive System Diseases
Lung Diseases
Respiratory Tract Diseases
Genetic Diseases, Inborn
Infant, Newborn, Diseases